Abstract:
Periostin is an extracellular matrix protein that is implicated in the biology of normal bone remodeling and in different cancer cell growth and metastasis. However, there is no information on the role of periostin in multiple myeloma (MM). Thus, we evaluated periostin in six myeloma cell lines in vitro; in the bone marrow plasma and serum of 105 newly diagnosed symptomatic MM (NDMM) patients and in the serum of 23 monoclonal gammopathy of undetermined significance (MGUS), 33 smoldering MM (SMM) patients, 30 patients at the plateau phase post-first-line therapy, 30 patients at first relapse and 30 healthy controls. We found high levels of periostin in the supernatants of myeloma cell lines compared with ovarian cancer cell lines that were not influenced by the incubation with the stromal cell line HS5. In NDMM patients the bone marrow plasma periostin was almost fourfold higher compared with the serum levels of periostin and correlated with the presence of fractures and of diffuse magnetic resonance imaging pattern of marrow infiltration. Serum periostin was elevated in NDMM patients compared with healthy controls, MGUS and SMM patients and correlated with advanced disease stage, high lactate dehydrogenase, increased activin-A, increased bone resorption and reduced bone formation. Patients at first relapse had also elevated periostin compared with healthy controls, MGUS and SMM patients, while even patients at the plateau phase had elevated serum periostin compared with healthy controls. These results support an important role of periostin in the biology of myeloma and reveal periostin as a possible target for the development of antimyeloma drugs. © 2016 The Author(s).
Notes:
Export Date: 18 February 2017References: Christoulas, D., Terpos, E., Dimopoulos, M.A., Pathogenesis and management of myeloma bone disease (2009) Expert Rev Hematol, 2, pp. 385-398;Norris, R.A., Moreno-Rodriguez, R., Hoffman, S., Markwald, R.R., The many facets of the matricellular protein periostin during cardiac development, remodeling, and pathophysiology (2009) J Cell Commun Signal, 3, pp. 275-286;
Cobo, T., Viloria, C.G., Solares, L., Fontanil, T., González-Chamorro, E., De Carlos, F., Role of periostin in adhesion and migration of bone remodeling cells (2016) PLoS One, 11, p. e0147837;
Merle, B., Bouet, G., Rousseau, J.C., Bertholon, C., Garnero, P., Periostin and transforming growth factor ?-induced protein (TGF?Ip) are both expressed by osteoblasts and osteoclasts (2014) Cell Biol Int, 38, pp. 398-404;
Bonnet, N., Garnero, P., Ferrari, S., Periostin action in bone (2015) Mol Cell Endocrinol, 432, pp. 75-82;
Rousseau, J.C., Sornay-Rendu, E., Bertholon, C., Chapurlat, R., Garnero, P., Serum periostin is associated with fracture risk in postmenopausal women: A 7-year prospective analysis of the OFELY study (2014) J Clin Endocrinol Metab, 99, pp. 2533-2539;
Kim, B.J., Rhee, Y., Kim, C.H., Baek, K.H., Min, Y.K., Kim, D.Y., Plasma periostin associates significantly with non-vertebral but not vertebral fractures in postmenopausal women: Clinical evidence for the different effects of periostin depending on the skeletal site (2015) Bone, 81, pp. 435-441;
Sakellariou, G.T., Anastasilakis, A.D., Bisbinas, I., Oikonomou, D., Gerou, S., Polyzos, S.A., Circulating periostin levels in patients with AS: Association with clinical and radiographic variables, inflammatory markers and molecules involved in bone formation (2015) Rheumatology (Oxford), 54, pp. 908-914;
Terpos, E., Kastritis, E., Christoulas, D., Gkotzamanidou, M., Eleutherakis-Papaiakovou, E., Kanellias, N., Circulating activin-A is elevated in patients with advanced multiple myeloma and correlates with extensive bone involvement and inferior survival; No alterations post-lenalidomide and dexamethasone therapy (2012) Ann Oncol, 23, pp. 2681-2686;
Kapoor, S., Periostin and its emerging role in systemic carcinogenesis (2014) Osteoporos Int, 25, pp. 1423-1424;
Underwood, T.J., Hayden, A.L., Derouet, M., Garcia, E., Noble, F., White, M.J., Cancer associated fibroblasts predict for poor outcome and promote periostin-dependent invasion in oesophageal adenocarcinoma (2015) J Pathol, 235, pp. 466-477;
Hu, F., Shang, X.F., Wang, W., Jiang, W., Fang, C., Tan, D., High-level expression of periostin is significantly correlated with tumour angiogenesis and poor prognosis in osteosarcoma (2016) Int J Exp Pathol, 97, pp. 86-92;
Contié, S., Voorzanger-Rousselot, N., Litvin, J., Clézardin, P., Garnero, P., Increased expression and serum levels of the stromal cell-secreted protein periostin in breast cancer bone metastases (2011) Int J Cancer, 128, pp. 352-360;
Kyle, R.A., Rajkumar, S.V., Criteria for diagnosis, staging, risk stratification and response assessment of multiple myeloma (2009) Leukemia, 23, pp. 3-9;
Slany, A., Haudek-Prinz, V., Meshcheryakova, A., Bileck, A., Lamm, W., Zielinski, C., Extracellular matrix remodeling by bone marrow fibroblast-like cells correlates with disease progression in multiple myeloma (2014) J Proteome Res, 13, pp. 844-854;
Merle, B., Garnero, P., The multiple facets of periostin in bone metabolism (2012) Osteoporos Int, 23, pp. 1199-1212;
Bonnet, N., Standley, K.N., Bianchi, E.N., Stadelmann, V., Foti, M., Conway, S.J., The matricellular protein periostin is required for SOST inhibition and the anabolic response to mechanical loading and physical activity (2009) J Biol Chem, 284, pp. 35939-35950;
Voskaridou, E., Christoulas, D., Papatheodorou, A., Oikonomopoulos, P., Komninaka, V., Repa, K., Circulating periostin is elevated in patients with hemoglobinopathies and correlates with bone mineral density in double heterozygous sickle-cell/betathalassemia patients; A novel marker of bone strength? (2013) Blood, 122, p. 3445. , (abstract);
Anastasilakis, A.D., Polyzos, S.A., Makras, P., Savvides, M., Sakellariou, G.T., Gkiomisi, A., Circulating periostin levels do not differ between postmenopausal women with normal and low bone mass and are not affected by zoledronic acid treatment (2014) Horm Metab Res, 46, pp. 145-149;
Fields, S.Z., Parshad, S., Anne, M., Raftopoulos, H., Alexander, M.J., Sherman, M.L., Activin receptor antagonists for cancer-related anemia and bone disease (2013) Expert Opin Invest Drugs, 22, pp. 87-101;
Eijken, M., Swagemakers, S., Koedam, M., Steenbergen, C., Derkx, P., Uitterlinden, A.G., The activin A-follistatin system: Potent regulator of human extracellular matrix mineralization (2007) Faseb J, 21, pp. 2949-2960;
Li, M., Li, C., Li, D., Xie, Y., Shi, J., Li, G., Periostin, a stroma-associated protein, correlates with tumor invasiveness and progression in nasopharyngeal carcinoma (2012) Clin Exp Metastasis, 29, pp. 865-877;
Xu, D., Xu, H., Ren, Y., Liu, C., Wang, X., Zhang, H., Cancer stem cell-related gene periostin: A novel prognostic marker for breast cancer (2012) PLoS One, 7, p. e46670;
Nuzzo, P.V., Rubagotti, A., Zinoli, L., Salvi, S., Boccardo, S., Boccardo, F., The prognostic value of stromal and epithelial periostin expression in human breast cancer: Correlation with clinical pathological features and mortality outcome (2016) BMC Cancer, 16, p. 95;
Nuzzo, P.V., Rubagotti, A., Argellati, F., Di Meglio, A., Zanardi, E., Zinoli, L., Prognostic value of preoperative serum levels of periostin (PN) in early breast cancer (BCa) (2015) Int J Mol Sci, 16, pp. 17181-17192;
Morra, L., Rechsteiner, M., Casagrande, S., Von Teichman, A., Schraml, P., Moch, H., Characterization of periostin isoform pattern in non-small cell lung cancer (2012) Lung Cancer, 76, pp. 183-190;
Tischler, V., Fritzsche, F.R., Wild, P.J., Stephan, C., Seifert, H.H., Riener, M.O., Periostin is up-regulated in high grade and high stage prostate cancer (2010) BMC Cancer, 10, p. 273;
Kyutoku, M., Taniyama, Y., Katsuragi, N., Shimizu, H., Kunugiza, Y., Iekushi, K., Role of periostin in cancer progression and metastasis: Inhibition of breast cancer progression and metastasis by anti-periostin antibody in a murine model (2011) Int J Mol Med, 28, pp. 181-186
Website
